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A B S T R A C T
Osteosarcoma (OS) is the most aggressive type of primary solid tumor that develops in bone. Whilst conven-
tional chemotherapy can improve survival rates, the outcome for patients with metastatic or recurrent OS re-
mains poor, so novel treatment agents and strategies are required. Research into new anticancer therapies has
paved the way for the utilisation of natural compounds as they are typically less expensive and less toxic com-
pared to conventional chemotherapeutics. Previously published works indicate that Agave exhibits anticancer
properties, however potential molecular mechanisms remain poorly understood. In the present study, we inves-
tigate the anticancer effects of Agave leaf extract in OS cells suggesting that Agave inhibits cell viability, colony
formation, and cell migration, and can induce apoptosis in OS cell lines. Moreover, Agave sensitizes OS cells to
cisplatin (CDDP) and radiation, to overcome chemo- and radio-resistance. We demonstrate that Agave extract
induces a marked decrease of Yes Associated Protein (YAP) and Tafazzin (TAZ) mRNA and protein expression
upon treatment. We propose an initial mechanism of action in which Agave induces YAP/TAZ protein degrada-
tion, followed by a secondary event whereby Agave inhibits YAP/TAZ transcription, effectively deregulating the
Nuclear Factor kappa B (NF-κB) p65:p50 heterodimers responsible for transcriptional induction of YAP and TAZ.
1. Introduction
Osteosarcoma (OS) is the most frequent primary tumor affecting
bone, and typically originates in the extremities of the long bones in
the legs. It is always associated with increasing pain [1,2]. OS shows a
bimodal age occurrence, arising frequently in children and teens aged
10–16 years, and in older adults usually over 40. Neoplastic cells show a
complex karyotype associated with chromosome instability, copy num-
ber variation and deregulation of many signalling pathways such as
Vascular Endothelial Growth Factor-Receptor (VEGF-R), Transforming
Growth Factor-beta (TGFβ), Wnt/β-catenin, Hippo/YAP, Hedgehog,
Notch and PI3K-Akt-mTOR [3,4]. First line treatment is intravenous
combinational chemotherapy (cisplatin (CDDP)/doxorubicin) [3]. For
Abbreviations: Cisplatin, CDDP; Cycloheximide, CHX; Epithelial to mesenchymal transition, EMT; Nuclear Factor kappa-light-chain-enhancer of activated B cells, NF-κB; Osteosarcoma,
OS; half-maximal effective concentration, EC50; half-maximal lethal concentration, LC50; cocktail protein inhibitors, CI; 4′, 6-diamidino-2- phenylindole, DAPI.
∗ Corresponding author. Oncogenomic and Epigenetic Unit, Molecular Chemoprevention Group, Department of Research, Diagnosis and Innovative Technologies, Translational Research
Area Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Roma, Italy.
∗∗ Corresponding author. Oncogenomic and Epigenetic Unit, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area Regina Elena National Cancer
Institute, Via Elio Chianesi, 53, 00144, Roma, Italy.
Email addresses: sabrina.strano@ifo.gov.it (S. Strano); giovanni.blandino@ifo.gov.it (G. Blandino)
1 These authors contribute equally to the work.
https://doi.org/10.1016/j.canlet.2018.06.021
Received 24 December 2017; Received in revised form 1 June 2018; Accepted 14 June 2018
Available online xxx
0304-3835/ © 2018.
Original Articles
UN
CO
RR
EC
TE
D
PR
OO
F
M. Ferraiuolo et al. Cancer Letters xxx (2018) xxx-xxx
patients with localized OS, surgical resection is an essential component
of the therapy, however if not feasible, radiation therapy can be used
to improve prognosis [5,6]. OS is frequently associated with chemo-
and radio-resistance due to the presence of cancer stem cell subpopula-
tions and Hippo/YAP signalling alterations [3,7]. The five-year survival
rate for patients with metastatic or recurrent disease has essentially re-
mained unchanged at approximately 20% [8,9]. New, effective OS an-
ticancer strategies are urgently required, paving the way for research
into less-toxic, cost-effective natural compounds that could be useful as
novel OS therapeutics.
The Hippo pathway is an evolutionarily conserved signalling path-
way that plays a key role in development, stem cell maintenance, re-
generation, cancer onset, and chemoresistance [7,10–12]. The Hippo
core comprises the Lats1/2-(Mob1-Sav1)-Mst1/2 protein kinases that
function as tumor suppressors. The core kinase cassette induces phos-
phorylation of the oncogenic Hippo transducers YAP and TAZ resulting
in their cytoplasmic retention and/or protein degradation [13]. Since
YAP and TAZ lack a DNA binding domain, they interact with vari-
ous DNA-binding transcription factors including TEADs/TEFs, β-catenin,
RUNX1/2 and Smads to drive transcription of their oncogenic target
genes. Interestingly, the Hippo pathway has been shown to cooperate
with p53 signalling to induce apoptosis, DNA damage repair, and senes-
cence [14].
The NF-κB family of transcription factors are key regulators of im-
mune development, immune responses, inflammation, and cancer [15].
In the absence of stimuli, NF-κB is inactivated and sequestered in the
cytoplasm through binding to the inhibitor protein IκBα; in the presence
of stimuli, the activated kinase IKK phosphorylates IκBα, promoting
its proteasomal degradation and NF-κB release. Thus, activated NF-κB
translocates into the nucleus to promote transcription of its target genes
[15]. NF-κB acts as dimer of different subunits: p65 (or RelA), RelB, p50
(obtained from p105 precursor), p52 (produced from p100 precursor),
and cRel.
In the present study, we observe that Agave natural extract inhibits
the survival and migration of OS cell lines, and sensitizes them to CDDP
and radiation treatments. We demonstrate that Agave mediates its an-
ticancer activity via increasing YAP and TAZ protein degradation, and
subsequently inhibiting the formation of NF-κB p65:p50 pro-transcrip-
tional heterodimers. These results suggest that targeting the Hippo path-
way may be an effective strategy to treat OS.
2. Materials and methods
2.1. Cell culture and reagents
Cell lines HFF-1, U-2 OS, Saos-2, HOS, MG-63, H1299, A549,
MDA-MB-231, SUM-159PT, MSTO-211H and MPP-89 were obtained
from the ATCC (Manassas, US) and cultured accordingly. Tumoural
cell lines were checked and tested for p53 status. Specifically, we used
wt-p53cell lines (U-2 OS, A549, MSTO-211H, MPP-89), mutant p53
(HOS, MDA-MB-231, SUM-159PT) and p53-null cells (Saos-2, MG-63,
H1299). U-2 OS cell line resistant to Cisplatin (CDDP) 4μg/mL (U-2
OS/CDDP 4μg/mL) was provided by “Laboratory of Experimental On-
cology” from the “Rizzoli Orthopedic Institute” [16] and cultured in
Iscoves's modified Dulbecco's Medium (IMDM; Life Technologies, Cal-
ifornia, USA) 10% FBS supplemented with CDDP 4μg/mL. Agave to-
tal extract from frozen leaf samples of Agave sisalana plant was pro-
vided in powder and characterized as previously described from the
Italian Aboca Society [17]. Saponins Diosgenin (Cat. D1634), Sarsasa-
pogenin (Cat. S8534) and Solasodine (Cat. SML1141) were purchased
from Sigma (Saint Louis, Missouri, US). Cisplatin (CDDP), doxorubicin,
methotrexate and isofosfamide were provided by the Pharmacy of the
“Regina Elena National Cancer Institute” in Rome. DAPI (4′, 6-di-
amidino-2- phenylindole, dihydrochloride, Sigma Cat. 32670) was used
to stain cell nuclei. Protease Inhibitor Cocktail (CI) (Cat. P8340),
MG-132 (Z-Leu-Leu-Leu-al, Cat. C2211), cycloheximide (CHX) (Cat.
01810), IL-6 (Cat. I1395), verteporfin (Cat. SML0534), dasatinib (Cat.
CDS023389) and pazopanib (Cat. CDS023580) were purchased from
Sigma.
2.2. Cell transfection
Transfections were performed using Lipofectamine 2000 (for plas-
mids) and Lipofectamine RNAiMax (for siRNA) (Life Technologies) ac-
cording to the manufacturer's recommendations.
siRNAs were purchased from Eurofins MWG (Ebersberg, Germany):
siGFP [18], siYAP [19], siTAZ is a pool of two independent siRNAs
mixed in equal amount [20]. To exclude unspecific effects, we previ-
ously performed YAP and TAZ silencing with two different siRNAs. Rep-
resentative data are showed in figures. Plasmids utilized were: pCD-
NA3-YAP-Flag [21], pCS2-TAZ-Flag [22], and pCS2-Ub-HA [23].
2.3. Viability, clonogenic, and wound healing migration assays
Viability, clonogenic and wound healing migration assays were per-
formed as previously described [24].
2.4. Radiation treatments
A number of 2×10⁠5cells was plated in 60mm plates and treated
after 24h as indicated. The day after, cells were placed in an irradia-
tion chamber and subjected to 0.08Gy/min Cs⁠137 γ-irradiation for 37.5s
and for 62.5s. This allowed obtaining 3Gy and 5Gy cumulative doses,
respectively. After additional 24h, cells were detached and plated in
96-well (1500cells per well). ATPlite assay (Perkin Elmer, Massachu-
setts, USA) was performed after 72h as previously described [24].
2.5. Cell extracts, immunoprecipitation and Western Blotting
Cell lysis, protein quantification, Immunoprecipitation (IP) and
Western Blot analysis were performed as previously described [24]. Pri-
mary antibodies are listed in Supplementary Table S2.
2.6. RNA extraction, reverse transcription and quantitative Real-Time PCR
RNA was extracted, reverse-transcribed and subjected to quantita-
tive Real-Time PCR (qPCR) as previously described [25]. Data were
analyzed using the relative standard curve method and normalized to
GAPDH. Primer sequences are listed in Supplementary Table S3.
2.7. Protein stability assay
Cells were treated with Vehicle or Agave as indicated and simultane-
ously treated with cycloheximide (CHX) 40μM for the indicated times.
Cells were subsequently lysed and subjected to Western Blotting as pre-
viously described.
2.8. Ubiquitination assay
A number of 1.6×10⁠6cells was transfected with the indicated plas-
mids as previously described and simultaneously treated as indicated.
After 18h, cells were treated with 25μM MG-132 for a further 6h. Pro-
tein extracts were immunoprecipitated as described and subjected to
Western Blotting. Antibody details are listed in Supplementary Table S2.
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2.9. Nuclear/cytoplasmic protein extraction
Nuclear/cytoplasmic protein extraction was performed as previously
described [26]. Refer to Supplementary Table S2 for antibody specifica-
tions.
2.10. Immunofluorescent staining
Cells were processed as previously described [17] and treated as in-
dicated for 72h. IL-6 treatments were performed using 100ng/mL for
30min before recovering cells. Antibodies specifications are listed in
Supplementary Table S2.
2.11. Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed and data were analyzed as previously
reported [20]. Refer to Supplementary Table S2 for antibody specifica-
tions. Primer sequences are listed in Supplementary Table S3.
2.12. Promoter analysis
FASTA sequences of human YAP1 (NM_001130145) and WWTR1
(TAZ) (NM_015472) promoters (4000 bp upstream of the TSS) were
downloaded from UCSC Genome Browser on-line database and pasted
into LASAGNA-Search 2.0 to identify predicted transcription factor
binding sites. TRANSFAC matrices were used for the analysis.
2.13. Statistical analyses
All experiments were performed at least three independent times and
the most representative results are shown. No samples were excluded
from the analysis. For statistical analysis, we used two-tailed t-tests for
comparison analysis between two populations, and the F-test ANOVA
and the post-hoc Tukey test for multiple comparisons analysis. All p-val-
ues were determined and statistical significance was set at *p < 0.01,
**p < 0.001.
3. Results
3.1. Agave reduces cell viability, colony formation, cell migration, and
sensitizes cells to CDDP
Searching for potential alternate OS therapeutics, we performed cell
viability assays testing 15 natural compounds on U-2 OS and Saos-2
OS cell lines (data not shown). We noted that of the 15 compounds
tested, Agave natural extract showed the greatest reduction in cell vi-
ability. We therefore focused on this extract and extended our analy-
sis to four OS cell lines: U-2 OS, Saos-2, HOS and MG-63. Dose-re-
sponse assays were performed using Agave treatment for 72h (Fig. 1A).
Table 1 shows the half-maximal effective concentration (EC50) and the
half-maximal lethal concentration (LC50) for each cell line. EC50 values
ranged from 3.67μg/mL in U-2 OS to 6.16μg/mL in HOS cells (Table
1). Interestingly, we found that Agave-induced killing effect was more
effective toward cancer cells. Indeed, human fibroblast HFF-1cells re-
sulted more resistant (EC50 159.03μg/mL) than OS cells in response to
Agave treatments; thereby suggesting that Agave is not toxic for nor-
mal cells, at least, for the amounts inducing OS cell death (Fig. 1A
and Table 1). For subsequent functional analyses, we selected the lower
dose of Agave 3.12μg/mL, which reduced cell viability by approxi-
mately 25% (Fig. 1A). We tested cell migratory ability after 24h of
Agave treatment using wound healing- (Fig. 1B–C) and transwell- (Fig.
1D) migration assays, and found that Agave impairs cell migration in
both U-2 OS and Saos-2cell lines.
The biggest challenge in OS therapy is overcoming chemoresistance
[3]. To determine whether Agave can improve the effectiveness of
CDDP as an apoptotic agent, we assayed Agave in combination with in-
creasing doses of CDDP for 72h (Fig. 1E–F). Agave extract sensitized
OS cells to CDDP, effectively reducing the EC50 (by 2.2-fold) and LC50
(by 2.9-fold) for U-2 OS and Saos-2cells (Table 2). Clonogenic assays
were then performed to assess colony formation ability using U-2 OS
and Saos-2cell lines treated with Agave and CDDP either alone or in
combination (Fig. 1G–H). Whilst CDDP was more effective than Agave
in reducing colony numbers, Agave potentiated CDDP's inhibitory ef-
fect in both cell lines. To test whether Agave treatment could overcome
chemoresistance to conventional OS treatments, we assayed the ability
of Agave to promote cell death of a CDDP-resistant OS cell line. To this
end, U-2 OS/CDDP 4μg/mL cells were treated with increasing doses of
CDDP (Fig. 1I and Table 3) and Agave (Fig. 1J and Table 3) for 72h.
Notably, we found that unlike CDDP, Agave promoted cell death of U-2
OS/CDDP 4μg/mL cells and had additive and synergistic effect with
CDDP in reducing OS cell viability (Fig. 1K).
Agave's inhibitory effect on cell viability was also tested in a va-
riety of other cancer cell lines (lung, mesothelioma and breast)
(Supplementary Fig. S1) demonstrating a consistent dose-dependent ef-
fect.
3.2. Agave decreases oncogenic YAP and TAZ protein levels and induces
apoptosis
As previously described, OS typically exhibits dysregulation of mul-
tiple signalling pathways, including Hippo/YAP [4]. Alterations in this
pathway have also been demonstrated to be a driver of chemo- and
radio-resistance in OS patients [7]. To determine the mechanism of
Agave's anticancer effects we investigated different signalling pathways
and focused on alterations within the Hippo pathway, specifically the
Hippo transducers YAP and TAZ. Agave decreased YAP and TAZ protein
expression after 24h in U-2 OS cells (Fig. 2A). Notably, Lats1 protein
level was unchanged, and TEA Domain transcription factor 1 (TEAD1)
only mildly down-regulated after 72h of Agave treatment. Reduced YAP
and TAZ expression was also observed in Saos-2, HOS and MG-63 lines
after 72h of Agave treatment (Fig. 2B). Treatment with CDDP alone did
not affect YAP and TAZ protein levels (Fig. 2C). Moreover, Agave in-
duced apoptosis by increasing Bax protein expression, as well as Caspase
3 and PARP cleavage (lanes 1–2, Fig. 2C), this effect is stronger com-
pared to that mediated by CDDP treatment alone (lanes 1 and 3, Fig.
2C), and appears to enhance CDDP's effect increasing Caspase 3 cleav-
age in combined treatment (lanes 3–4, Fig. 2C). Conventional OS ther-
apies comprise also combined treatments with doxorubicin, methotrex-
ate and isofosfamide [3]. We tested doxorubicin effect on U-2 OS and
Saos-2 treated cells for 72h (Fig. 2D–E) calculating EC50 and LC50 for
each cell line (Table 4), then we selected the dose of 100nM to test YAP
and TAZ protein expression (Fig. 2F). We found that doxorubicin treat-
ment for 72h induced YAP and TAZ protein levels in U-2 OS cell line
supporting previous published results [7]. Treatment with methotrexate
100μM for 72h, induced YAP and TAZ as well, whereas isofosfamide
250μM induced YAP upregulation but not TAZ modulation after 72h of
treatment (Fig. 2F). We also found that Agave improved the killing ef-
fects of radiotherapy, when used (3.12μg/mL) in combination with 3Gy
or 5Gy of Cs⁠137 γ-radiation. Agave extract sensitized OS cells to radia-
tion, effectively reducing cell viability compared to the irradiated sam-
ples alone (Fig. 2G–H).
These data suggest that Agave reduces cell viability and sensitizes
OS cells to chemo- and radio-therapy by down-regulating YAP and TAZ
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Fig. 1. Agave exerts anticancer effects on osteosarcoma cell lines. (A) Osteosarcoma cell lines were treated with Vehicle control (EtOH) or increasing concentrations of Agave for 72h
before being analyzed by ATPlite assay. The percentage cell viability normalized to control is shown, with values representing mean±STDEV of n=3 independent experiments. Wound
healing- (B–C) and transwell- (D) migration assays were performed on U-2 OS (B, D) and Saos-2 (C, D) cell lines after treatment with Agave (3.12 μg/mL) or Vehicle for 24 h. His-
tograms represent the percentage of wound width (B–C) or migrated cells (D) normalized to the relevant controls. Values represent mean ± STDEV from n = 3 independent experiments,
*p < 0.01 **p < 0.001. Osteosarcoma cell lines U-2 OS (E) and Saos-2 (F) were treated with either Vehicle (CTRL) or Agave (3.12μg/mL) in combination with increasing doses of cis-
platin (CDDP) for 72h. The percentage viability of Agave treatment alone was subtracted from each CDDP or CTRL value (corrected value), then these data were normalized to the CTRL
corrected value. Values shown represent mean±STDEV from n=3 independent experiments. U-2 OS (G) and Saos-2 (H) cell lines were treated with Vehicle, Agave (3.12 μg/mL), and/
or CDDP (0.6 μg/mL) for 24 h after seeding for clonogenic assays. Histograms represent the mean percentage of colonies ± STDEV normalized to Vehicle control from n = 3 independent
experiments, ANOVA **p < 0.001. Images underneath histograms are representative stained culture dishes used for counting colonies. U-2 OS/CDDP 4 μg/mL cell line was treated with
increasing concentrations of CDDP (I) or Agave with a fixed dose of CDDP (4μg/mL) (J) for 72 h before being analyzed by ATPlite assay. Histograms represent the percentage of cell via-
bility normalized to control, with values representing mean ± STDEV of n = 3 independent experiments, ANOVA *p < 0.01 **p < 0.001. (K) Combination index versus the fractional ef
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fect obtained from U-2 OS/CDDP 4μg/mL cells pretreated with Agave extract (3.12μg/mL) for 24h and subsequently with CDDP (1–8μg/mL) for 72h. Combination index was calculated
using Calcusyn software.
Table 1
Treatment with Agave reduces cell viability. The half-maximal effective concentration (EC50) and the half-maximal lethal concentration (LC50) values for osteosarcoma and HFF-1cell
lines treated with Agave, calculated using Compusyn software from the dose-response curves in Fig. 1A.
Phytocompound Agave treatments
U-2 OS Saos-2 HOS MG-63 HFF-1
EC50 (μg/
mL)
LC50 (μg/
mL)
EC50 (μg/
mL)
LC50 (μg/
mL)
EC50 (μg/
mL)
LC50 (μg/
mL)
EC50 (μg/
mL)
LC50 (μg/
mL)
EC50 (μg/
mL)
LC50 (μg/
mL)
3.67 5.21 4.8 6.3 6.16 9.38 4.39 7.81 159.03 116.67
Table 2
Agave sensitizes osteosarcoma cells to cisplatin. The half-maximal effective concentration
(EC50) and the half-maximal lethal concentration (LC50) values for osteosarcoma cell
lines treated with cisplatin (CDDP) in combination with Agave (3.12μg/mL) or EtOH con-
trol (CTRL), calculated using Compusyn software from the dose-response curves in Fig.
1E–F.
Samples U-2 OS Saos-2
CDDP
EC50
(μg/mL)
CDDP
LC50 (μg/
mL)
CDDP
EC50 (μg/
mL)
CDDP
LC50 (μg/
mL)
CTRL 1.66 4.4 2.89 4.4
Agave
3.12 μg/
mL
0.76 1.5 1.4 1.5
Table 3
Agave sensitizes U-2 OS CDDP resistant cell line to cisplatin. The half-maximal effective
concentration (EC50) and the half-maximal lethal concentration (LC50) values for U-2 OS/
CDDP 4μg/mL osteosarcoma cell line treated with increased doses of cisplatin (CDDP) or
Agave, calculated using Compusyn software from the dose-response curves in Fig. 1I–J.
Cell line
CDDP
EC50
(μg/mL)
CDDP
LC50
(μg/mL)
Agave
EC50
(μg/mL)
Agave
LC50
(μg/mL)
U-2 OS/
CDDP 4 μg/
mL
> 32 26.67 50.73 37.5
that are known to function as oncogenes in OS cells [4,7]. Indeed, YAP/
TAZ silencing sensitized OS cell lines to Agave (Fig. 3A), reducing the
EC50 and LC50 concentrations by 4.2- and 2.2-fold, respectively (Table
5). Moreover, silencing of YAP and TAZ reduced the clonogenic and
migratory capabilities of both U-2 OS and Saos-2cell lines (Fig. 3B–D
and Supplementary Figs. S2A–B). Among FDA-approved YAP and TAZ
inhibitors, stand out verteporfin, dasatinib and pazopanib [27,28]. To
confirm that YAP and TAZ exert an oncogenic crucial role in OS cell sur-
vival, we assayed U-2 OS and Saos-2cell lines with increased doses of
verteporfin (Fig. 3E and Supplementary Fig. S2C), dasatinib (Fig. 3F and
Supplementary Fig. S2D) and pazopanib (Fig. 3G and Supplementary
Fig. S2E) and we calculated the EC50 and LC50 for each synthetic
compound in both cell lines (Table 6). We found that the YAP/TAZ
inhibitors significantly reduced OS cells viability in a dose-dependent
manner. Altogether these findings mirror an important role of YAP and
TAZ in the chemoresistance of osteosarcoma cells thereby suggesting
YAP/TAZ targeting as a therapeutic approach to improve the outcome
of OS patients.
3.3. Saponins in Agave extract down-regulate YAP and TAZ protein levels
To dissect the molecular mechanism by which Agave extract func-
tions, we investigated the effect of saponins, which are the most abun-
dant compounds present in Agave natural extract among that with
recognised anticancer effects (Supplementary Table S1) [29,30]. We
assayed Diosgenin, Sarsasapogenin and Solasodine synthetic steroidal
saponins using viability assays (Fig. 4A and Table 7), then treated cells
with sub-lethal doses of each compound to test their effect on YAP
and TAZ. Although less effective when compared to Agave, Diosgenin
and Solasodine reduced both YAP and TAZ protein abundance, whilst
Sarsasapogenin significantly reduced YAP at the selected concentrations
(Fig. 4B). Lats1 and TEAD1 down-regulation were not observed (Fig.
4B). Interestingly, Diosgenin and Solasodine combined treatments in-
duced a synergistic down-regulation of YAP and TAZ proteins to a simi-
lar extent of Agave (Fig. 4C).
3.4. Agave enhances YAP and TAZ protein degradation as an early event
To investigate how Agave can modulate YAP and TAZ protein lev-
els we performed protein stability assays by treating cells with cyclo-
heximide (CHX) in the presence or absence of Agave, then harvest-
ing cells at different time points. Agave treatment resulted in signif-
icantly reduced YAP and TAZ protein levels at 24 and 16h, respec-
tively (Fig. 4D–F). Agave-induced YAP/TAZ reduction was mediated by
ubiquitin-dependent proteasomal degradation as indicated by the in-
creased abundance of ubiquitinated YAP/TAZ (Fig. 4G–H). The rapid
loss of YAP and TAZ proteins suggests that ubiquitin-mediated YAP/TAZ
degradation is an early event following Agave administration.
3.5. Agave reduces YAP and TAZ mRNA as a late event
In addition to decreasing YAP/TAZ protein abundance, we investi-
gated whether Agave reduces YAP and TAZ mRNA expression. Treat-
ment with Agave for 72h resulted in a significant decrease in YAP
(2.3-fold, p<0.001) and TAZ (1.9-fold, p<0.001) mRNA (Fig. 5A–B).
This reduced the ability of YAP and TAZ to function as transcrip-
tional co-activators since the expression of their target genes: Connec-
tive Tissue Growth Factor (CTGF), Ankyrin Repeat Domain-containing pro-
tein 1 (ANKRD1) and Minichromosome maintenance Complex component
7 (MCM7) were also significantly down-regulated (Fig. 5C–E). Interest-
ingly, treatment with CDDP alone decreased YAP and TAZ expression,
as well as their transcriptional function (determined by target gene ex-
pression) by 96h (Fig. 5A–E). This is consistent with the results showed
in Fig. 2C in which CDPP alone did not modulate YAP and TAZ protein
levels after 72h of treatment. Importantly however, the observed effect
was less than for Agave either alone or in combination with CDDP (Fig.
5A–E). TEAD1 mRNA was slightly decreased (1.2 fold, p<0.01) after
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Fig. 2. Agave sensitizes osteosarcoma cells to chemo- and radio-therapy by down-regulating YAP and TAZ. (A) U-2 OS cells were treated with Agave (3.12μg/mL) for 24, 48 or 72h, or
EtOH as Vehicle control (0h), then subjected to Western Blot analysis as indicated. GAPDH was used as a loading control. Numbers underneath immunoblots represent normalized protein
amount quantified using Alliance (UVITEC) Software. Values shown are representative from n=3 independent experiments. (B) Saos-2, HOS and MG-63cell lines were treated with Agave
(3.12μg/mL) or Vehicle for 72h, and (C) U-2 OS cells were treated with Vehicle, Agave (3.12μg/mL) and/or CDDP (0.6μg/mL) for 72h before being subjected to Western Blot analysis as
indicated. GAPDH was used as a loading control. Numbers underneath immunoblots represent normalized protein amount quantified using Alliance (UVITEC) Software. Values shown are
representative from n=3 independent experiments. U-2 OS (D) and Saos-2 (E) were treated with Vehicle control (DMSO) or increasing concentrations of doxorubicin for 72h before being
analyzed by ATPlite assay. The percentage cell viability normalized to control is shown, with values representing mean±STDEV of n=3 independent experiments. (F) U-2 OS cells were
treated with Vehicle control (DMSO), doxorubicin (100nM), methotrexate (100μM) or isofosfamide (250μM) for 72h before being subjected to Western Blot analysis as indicated. GAPDH
was used as a loading control. Numbers underneath immunoblots represent normalized protein amount quantified using Alliance (UVITEC) Software. Values shown are representative
from n=3 independent experiments. U-2 OS cells were pre-treated with Vehicle control (EtOH) or Agave (3.12μg/mL) before being subjected to Cs⁠137 γ-irradiation reaching a 3Gy (G) or
5Gy (H) cumulative dose. ATPlite assay was performed after 72 h and the percentage cell viability, normalized to control, is shown in histograms, with values representing mean ± STDEV
of n = 3 independent experiments, ANOVA **p < 0.001.
72h of Agave or CDDP treatment (Supplementary Fig. S2F), suggest-
ing non-specific regulation. LATS1 and LATS2 were not affected by any
treatment (Supplementary Figs. S2G–H).
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Table 4
Doxorubicin treatments in OS cell lines. The half-maximal effective concentration (EC50)
and the half-maximal lethal concentration (LC50) values for U-2 OS and Saos-2 osteosar-
coma cell line treated with increased doses of Doxorubicin (Doxo), calculated using Com-
pusyn software from the dose-response curves in Fig. 2D–E.
Cell line Doxo EC50 (μM) Doxo LC50 (μM)
U-2 OS 0.096 0.084
Saos-2 0.322 0.232
3.6. Agave down-regulates YAP and TAZ mRNA by inhibiting NF-κB
transcriptional activator function
To investigate the observed transcriptional inhibition mediated by
Agave, we analyzed the promoter sequence of YAP and TAZ for tran-
scription factor binding sites using LASAGNA-Search 2.0. Notably, we
found multiple consensus binding sites for NF-κB p65/p50 homo- and
hetero-dimers within YAP (Supplementary Fig. S2I) and TAZ
(Supplementary Fig. S2J) promoters. This was very intriguing because
NF-κB transcription factors play an oncogenic role in various cancers
and have been shown to promote metastasis and chemoresistance in OS
[3,31,32].
To determine whether the NF-κB consensus-binding sites identified
within the YAP and TAZ promoters are linked to their transcriptional
regulation by Agave, we performed ChIP analysis using NF-κB p65 and
p50 subunits, and p300 histone acetyltransferase as control of transcrip-
tionally active chromatin for two (YAP) and three (TAZ) predicted sites
(Fig. 6A). Using the H1H2BA sequence as a non-modulated control (Fig.
6B), we observed that treatment with Agave decreased NF-κB p65/p50
recruitment to YAP's first putative binding site (Fig. 6C), and reduced
p65 recruitment, whilst simultaneously increasing p50 binding, at YAP's
second binding site (Fig. 6D). Agave treatment reduced p300 histone
acetylase recruitment to both YAP binding sites (Fig. 6C–D), indicating
impairment of YAP transcription. Similarly, Agave reduced NF-κB p65/
p50 and p300 recruitment to all three TAZ binding sites (Fig. 6E–G). Of
particular note, TAZ's first binding site was strongly regulated by NF-κB
p65:p65 homo-dimers, and Agave treatment abolished this recruitment
(Fig. 6E).
Since NF-κB transcription factors bind to and regulate YAP and TAZ
transcription (Fig. 6), we subsequently investigated whether Agave reg-
ulates NF-κB protein expression. Treatment of U-2 OS cells with Agave
for 48h resulted in significant accumulation of NF-κB p50, and a slight
decrease of NF-κB p65 (Fig. 7A). Treatment of Saos-2, MG-63 and HOS
cell lines showed a consistent pattern of p65 and p50 expression after
72h (Fig. 7B). As described previously, NF-κB functions as dimers to
either activate (p65:p65 and p65:p50) or repress (p50:p50) gene tran-
scription [15]. In addition to total abundance, the relative ratio of differ-
ent subunits determines the outcome of NF-κB signalling [15]. Quanti-
tation of p65/p50 protein ratios revealed that Agave treatment strongly
favours the accumulation of NF-κB inhibitory subunit p50 in all tested
cell lines (Fig. 7C).
NF-κB dimers need to be localized to the nucleus to exert their tran-
scriptional effect. We thus investigated the sub-cellular localization of
NF-κB subunits following Agave treatment using nuclear/cytoplasmic
fractionation. Agave treatment increased nuclear accumulation of p105
(p50 precursor) and p50, and simultaneously reduced p65 localization
to the nucleus (Fig. 7D–E). These data are consistent with immunofluo-
rescent staining for NF-κB p105/p50 in the absence and presence of IL-6
(to activate NF-κB signalling) (Fig. 7F–G), and NF-κB p65 (Fig. 7H–I),
following treatment with Agave. Finally, consistent with the altered ex-
pression and localization of NF-κB subunits induced by Agave, the ex
pression of various NF-κB target genes was significantly reduced (Fig.
7J).
4. Discussion
Agave natural extract is known to exert prebiotic and immunomod-
ulatory effects, as well as putative anticancer activity in colorectal and
cervical cancer cells [33–35]. Here, we tested the anti-tumorigenic po-
tential of Agave in OS cell lines, demonstrating that it can reduce cell vi-
ability, impair migration and colony formation, and can sensitize cells to
CDDP and radiation therapies. We found that conventional chemother-
apeutic drugs can induce YAP and TAZ protein expression. This might
lead to YAP/TAZ-mediated increased chemoresistance of OS cells. This
effect is minimized in the presence of Agave due to its ability to signif-
icantly downregulate YAP and TAZ protein expression. Indeed, Agave
treatment down-regulates YAP and TAZ protein expression while direct
silencing of YAP/TAZ in OS lines reduced cell survival, colony forma-
tion and migration capability. Consistently with a previous publication,
Agave-induced apoptosis occurs irrespective to TP53 status [35].
Our findings support that of multiple reports, identifying an onco-
genic role for YAP and TAZ in OS [4,7]. YAP/TAZ are frequently overex-
pressed in human OS samples, correlating with target gene expression,
OS staging and overall patient survival [4,36]. Further, YAP suppression
impairs OS cell proliferation and migration in vitro, and reduces tumor
growth in vivo [4]. Mechanistically, up-regulation of YAP in osteo-tis-
sues is mediated by Sox2 inhibition of NF2 and Kibra, which are acti-
vators of the Hippo pathway [37], and by activation of Hedgehog sig-
nalling via Hippo pathway crosstalk [4]. In addition, RASSFs, NF2 and
Mob1 tumor suppressor proteins are frequently mutated in OS, resulting
in increased YAP and TAZ activation [4]. Importantly, there is good ev-
idence for the involvement of YAP/TAZ in inducing chemo-, radio- and
molecular targeted therapy-resistant OS [7,38].
Agave extract is a complex blend of compounds amongst which sa-
pogenins and saponins stand out as bioactive components with mul-
tiple functions. Unlike Agave, which is poorly studied, saponins have
been widely investigated, with numerous reports citing their antimi-
crobial [39], pro-apoptotic [40], immunomodulatory [41], neuroprotec-
tive [42], anti-proliferative [30] and anti-migratory properties in vari-
ous cancer cell lines [43–45]. At high doses (>100μM), saponins ex-
ert a cytotoxic effect by disrupting cell membranes. At low doses how-
ever, they induce apoptosis by multiple mechanisms including activa-
tion of Tumor Necrosis Factor-Receptor (TNF-R) and FAS-L receptors,
cleavage of Caspase 3 and 9, and induction of p53 by inhibiting Mouse
Double Minute 2 homolog (Mdm2) [46–49]. They also block cell pro-
liferation [50,51], impair migration and EMT [29], and regulate vari-
ous signalling pathways including PI3K/Akt, MAPK and NF-κB [52–56].
Consistent with saponins' tumor suppressive properties, we demonstrate
that synthetic saponins reduce cell viability, and down-regulate YAP/
TAZ abundance, although to a lesser extent than Agave itself. Neverthe-
less, combined treatments of saponins show a synergistic effect recapit-
ulating YAP and TAZ down-regulation mediated by Agave treatments.
This is consistent with previous reports demonstrating that the anti-in-
flammatory properties of Agave extract, mediated by NF-κB modulation,
could be partially recapitulated by saponins [57–59]. In detail, saponins
reduce NF-κB activity and its binding to DNA either by preventing IκB
degradation [57,58], or increasing SIRT1 levels, resulting in reduced
NF-κB p65 acetylation and subsequent transcriptional activation [59].
This might be the mechanism of Agave's action on NF-κB in this study.
However, due to the complexity of Agave extract, it is likely that a com-
bination of active components could activate/inhibit multiple signalling
pathways simultaneously, to produce a greater overall effect.
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Fig. 3. Down-regulation of YAP and TAZ oncogenes sensitizes cells to Agave treatments. (A) U-2 OS cells transfected with siGFP (control), siYAP, siTAZ or siYAP/siTAZ were treated with
increasing doses of Agave diluted in Vehicle. Values represent the mean percentage viability±STDEV for each condition (n=3), determined by ATPlite assay. (B) U-2 OS and Saos-2 cells
were transfected with siGFP (control), siYAP, siTAZ or siYAP/siTAZ and subjected to clonogenic assays. Histograms show the mean percentage of colonies ± STDEV normalized to siGFP
from n = 3 independent experiments, ANOVA **p < 0.001. Images underneath histograms are representative stained culture dishes used for counting colonies. U-2 OS (C) and Saos-2
(D) cells were transfected with siGFP (control), siYAP, siTAZ or siYAP/siTAZ and subjected to wound healing assays. Histograms show the mean percentage of wound width ± STDEV
normalized to siGFP from n = 3 independent experiments, ANOVA *p < 0.01 **p < 0.001. Images underneath histograms are representative of the wounded areas used for measuring
wound opening. U-2 OS cells were treated with Vehicle control or increasing concentrations of YAP/TAZ inhibitors verteporfin (E), dasatinib (F) or pazopanib (G) for 72h before being
analyzed by ATPlite assay. The percentage cell viability normalized to control is shown, with values representing mean±STDEV of n=3 independent experiments.
We propose that Agave initially induces YAP and TAZ protein desta-
bilization by promoting ubiquitin-dependent proteasomal degradation.
Subsequently, Agave impairs YAP and TAZ transcription by regulating
NF-κB expression, and consequently NF-κB subunit recruitment to YAP
and TAZ promoter sequences. Indeed, we suggest for the first time that
NF-κB subunits bind directly to YAP/TAZ promoters to activate their
transcription.
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Table 5
YAP and TAZ depletion sensitizes osteosarcoma cells to Agave. The half-maximal effective
concentration (EC50) and the half-maximal lethal concentration (LC50) values for Agave
treatment of siGFP (control), siYAP, siTAZ, or siYAP/siTAZ U-2 OS cell lines, analyzed us-
ing Compusyn software from the dose-response curves in Fig. 3A.
Samples Agave Agave
EC50 (μg/mL) LC50 (μg/mL)
siGFP 7.6 5.2
siYAP 4 4
siTAZ 3.8 4
siYAP/siTAZ 1.8 2.4
Table 6
YAP and TAZ inhibitors reduce osteosarcoma cell viability. The half-maximal effective
concentration (EC50) and the half-maximal lethal concentration (LC50) values for U-2
OS and Saos-2cells treated with the YAP/TAZ inhibitors verteporfin, dasatinib and pa-
zopanib, calculated using Compusyn software from the dose-response curves in Fig. 3E–G
and Supplementary Figs. S2C–E.
Synthetic
compounds U-2 OS Saos-2
EC50
(μM)
LC50
(μM)
EC50
(μM)
LC50
(μM)
Verteporfin 39.45 31.25 19.93 15.58
Dasatinib 0.174 0.127 1.12 1.54
Pazopanib 46.85 105 49.8 31.25
We considered that Agave's modulation of NF-κB could directly regu-
late apoptosis and chemosensitivity, bypassing YAP/TAZ transcriptional
regulation [3,15]. Saponins cooperate with CDDP to induce reactive
oxygen species production, resulting in apoptosis [29]. Chemical in-
hibitors of NF-κB (parthenolide and BRM270) sensitize OS to chemo-
and radio-therapies, and activate apoptosis [60–62]. Moreover, NF-κB
inhibition can sensitize cells to chemotherapeutics via up-regulation of
IL-6, an activator of NF-κB signalling [60].
Data presented here, indicate that YAP/TAZ as well as NF-κB are
mediators of Agave-induced anti-proliferative, anti-migratory and
pro-apoptotic effects in OS cell lines, and possibly in OS of animals and
human patients. We show that Agave induces YAP/TAZ protein degra-
dation as an early event, and subsequently impairs YAP and TAZ tran-
scription by inactivating NF-κB (Fig. 8). We propose that Agave-me-
diated YAP/TAZ down-regulation and NF-κB inactivation result in a
pro-apoptotic, anti-migratory phenotype with enhanced chemo- and ra-
dio-sensitivity. OS could therefore potentially be targeted by drugs that
have recently emerged as inhibitors of the critical YAP/TAZ-TEAD com-
plexes, which drive transcription of proliferative and anti-apoptotic
genes. Among YAP/TAZ inhibitors, verteporfin was shown to inhibit
YAP-induced overgrowth of liver in animal models [27]. Translocation
of YAP/TAZ to the nucleus was shown to be blocked by two FDA-ap-
proved tyrosine kinase inhibitors, dasatinib and pazopanib [28], and the
egress of YAP from the nucleus was facilitated by dobutamine, sympa-
thomimetic drug used in the treatment of heart failure [63]. Here we
show that verteporfin, dasatinib and pazopanib reduce OS cell viabil-
ity in a dose-dependent manner. These results highlight that YAP and
TAZ exert a key oncogenic pro-survival role in osteosarcoma and sug-
gest that YAP and TAZ inhibition could be a promising strategy for treat-
ing osteosarcoma. It is anticipated that new therapeutic compounds that
inhibit YAP/TAZ-TEAD will emerge soon. Natural compounds offer ad-
vantages over traditional chemotherapies as they typically exhibit low
toxicity, are associated with low production costs, and offer the poten-
tial for multi-faceted mechanisms of action. Such new drugs for YAP/
TAZ could be complemented with selected saponins of Agave to bet-
ter control and manage OS. Agave/saponin-mediated NF-κB inactivation
could be of interest for the treatment of other tumours in which NF-κB is
known to play an oncogenic role, including myeloid malignancies [64],
breast [65], lung [66], liver [67] and ovarian [68] cancers. Similarly,
for tumours in which YAP/TAZ play critical oncogenic roles [12,69].
We advocate that Agave natural extract is a promising agent to treat OS,
either independently, or as an adjuvant to reduce the intrinsic toxic side
effects of chemotherapeutics.
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Fig. 4. Agave induces YAP and TAZ protein degradation. (A) U-2 OS cells were treated with Vehicle (EtOH) or increasing concentrations of Diosgenin, Sarsasapogenin and Solasodine
synthetic saponins for 72h before being analyzed by ATPlite assay. The percentage cell viability normalized to control is shown, with values representing mean±STDEV of n=3 in-
dependent experiments. (B) U-2 OS cells were treated with Vehicle, Diosgenin (10μM), Sarsasapogenin (15μM) or Solasodine (10μM) for 72h before being subjected to Western Blot
analysis as indicated. GAPDH was used as a loading control. Numbers underneath immunoblots represent normalized protein amount quantified using Alliance (UVITEC) Software. Val-
ues shown are representative from n=3 independent experiments. (C) U-2 OS cells were treated with Vehicle (EtOH), saponins alone or in combined treatments, or Agave extract as
indicated for 72 h before being subjected to Western Blot analysis. GAPDH was used as a loading control. Histograms represent normalized protein amount quantified using Alliance
(UVITEC) Software. Values shown are representative from n = 3 independent experiments, ANOVA **p < 0.001. (D) U-2 OS cells were treated with Vehicle or Agave (3.12μg/mL) in
combination with cycloheximide (CHX, 40μM) for 16, 24 or 40h, or DMSO (0h). Cell extracts were then subjected to Western Blotting with the indicated antibodies and quantified using
Alliance (UVITEC) Software. The quantitated protein level at each time point for YAP (E) and TAZ (F) was normalized to that of GAPDH. U-2 OS cells were co-transfected with Flag-
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tagged YAP (G) or TAZ (H) as well as HA-tagged Ubiquitin before being treated with Vehicle or Agave (3.12 μg/mL) in combination with MG-132 (25 μM) for 6 h. Protein lysates were
then subjected to immunoprecipitation using anti-IgG or anti-Flag antibodies. Inputs recovered from anti-IgG IPs were loaded onto gels and subjected to immunoblot together with IP
samples. Arrows indicate ubiquitinated proteins. Histograms underneath immunoblots (G–H) show ubiquitinated proteins normalized to each IP signal. Quantification was performed
using Alliance (UVITEC) Software. Values represent mean ± STDEV of n = 3 independent experiments, ANOVA **p < 0.001.
Table 7
Saponins treatment reduces osteosarcoma cell viability. The half-maximal effective con-
centration (EC50) and the half-maximal lethal concentration (LC50) values for U-2 OS
cells treated with synthetic saponins Diosgenin, Sarsasapogenin and Solasodine, calculated
using Compusyn software from the dose-response curves in Fig. 4A.
Synthetic compounds EC50 (μM) LC50 (μM)
Diosgenin 15.93 12.5
Sarsasapogenin 29.29 20
Solasodine 4.4 17.5
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Fig. 5. Agave transcriptionally down-regulates YAP and TAZ. U-2 OS cells were treated with Vehicle (EtOH), Agave (3.12μg/mL), and/or CDDP (0.6μg/mL) for the indicated times before
being subjected to Real Time qPCR analysis. Histograms show the mean±STDEV mRNA level of YAP (A), TAZ (B), CTGF (C), ANKRD1 (D), and MCM7 (E) normalized to GAPDH (n = 3),
ANOVA *p < 0.01 **p < 0.001.
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Fig. 6. Agave inhibits NF-κB recruitment onto YAP and TAZ promoters. (A) Schematic representation of the relative position of the putative NF-κB binding sites within the YAP and TAZ
promoters. Different sites are highlighted in different colors, which are consistent with that used for sequences showed in Supplementary Figs. S2I–J. U-2 OS cells were treated with Vehicle
(EtOH) or Agave (3.12μg/mL) for 72h before being analyzed by ChIP. Samples were immunoprecipitated with antibodies against IgG, NF-κB p65, NF-κB p50 or p300 and then subjected
to qPCR analysis. Histograms shows the mean fold enrichment±STDEV (n=3) for H1H2BA (B), and the putative NF-κB binding sites within the YAP (C–D) and TAZ (E–G) promoters,
ANOVA **p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 7. Agave down-regulates NF-κB transcriptional function. (A) U-2 OS cells were treated with Agave (3.12μg/mL) for 24, 48 or 72h, or EtOH as Vehicle control (0h), then subjected
to Western Blot analysis as indicated. GAPDH was used as a loading control. Numbers underneath immunoblots represent normalized protein amount quantified using Alliance (UVITEC)
Software. Values shown are representative from n=3 independent experiments. (B) U-2 OS, Saos-2, HOS and MG-63cells were treated with Agave (3.12μg/mL) or Vehicle for 72h before
being subjected to Western Blot analysis. The abundance of NF-κB p65 and NF-κB p50 was quantified using Alliance (UVITEC) Software and the NF-κB p65/p50 ratio was determined.
The relative ratios are shown in (C). Values represent mean ± STDEV (n = 3), with U-2 OS cells treated with Vehicle normalized to 1, **p < 0.001. (D) U-2 OS cells were treated with
Vehicle or Agave (3.12μg/mL) for 72h before being subjected to nuclear/cytoplasmic fractionation followed by Western Blot analysis. H1 (nuclear) and α-Tubulin (cytoplasmic) were
used as loading controls. The nuclear/cytoplasmic ratios for NF-κB p105, p50 and p65 were determined (E). Values represent mean ± STDEV (n = 3), with U-2 OS cells treated with
Vehicle normalized to 1, ANOVA **p < 0.001. (F, H) U-2 OS cells were treated with Vehicle or Agave (3.12μg/mL) either in the absence or presence of IL-6 (100ng/mL) for 72h. Cells
were then stained for NF-κB p105/p50 (F), or p65 (H) with nuclei marked by DAPI staining. Nuclear and cytoplasmic signal was quantified using ImageJ software, and the relative
mean±STDEV for NF-κB p105/p50 (G) and NF-κB p65 (I) is shown, with cells treated with Vehicle normalized to 1, n = 3 ANOVA **p < 0.001. (J) U-2 OS cells were treated with Vehi
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cle or Agave (3.12 μg/mL) for 72 h before being subjected to Real Time qPCR analysis. The mean mRNA level ± STDEV (n = 3) for each target gene is shown, with cells treated with
Vehicle normalized to 1, ANOVA **p < 0.001.
Fig. 8. Proposed model of Agave's anticancer activity in osteosarcoma. (A) NF-κB p65:p50 and/or NF-κB p65:p65 dimers bind to YAP and TAZ promoters inducing p300 recruitment and
transcriptional activation. YAP and TAZ activated proteins, translocate into the nucleus to activate transcription of oncogenic targets genes CTGF, ANKRD1 and MCM7. (B) Agave treat-
ment promotes YAP/TAZ ubiquitin-dependent proteasomal degradation, reducing their nuclear translocation. Moreover, Agave down-regulates NF-κB p65 and promotes its cytoplasmic
sequestration, whereas NF-κB p50 is up-regulated and enriched in the nuclear compartment. YAP and TAZ transcription is therefore strongly diminished, as is their downstream targets.
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